Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings

Rafael Parra Lopez; Laszlo Nemes; Victor Jimenez-Yuste; Luminita Rusen; Ana R. Cid; Robert J. Charnigo; James A. Baumann; Lynne Smith; Joan M. Korth-Bradley; Pablo Rendo

doi:10.1160/TH14-09-0760

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2015; 114(04): 676-684
DOI: 10.1160/TH14-09-0760

Coagulation and Fibrinolysis

Schattauer GmbH

Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings

Authors

Rafael Parra Lopez

¹Banc de Sang i Teixits, Hospital Vall d’Hebron, Barcelona, Spain
Laszlo Nemes

²National Haemophilia Center and Haemostasis Department, State Health Center, Budapest, Hungary
Victor Jimenez-Yuste

³La Paz University Hospital, Madrid, Spain
Luminita Rusen

⁴National Institute for Transfusional Hematology, Bucharest, Romania
Ana R. Cid

⁵Thrombosis and Haemostasis Unit, University Hospital La Fe, Valencia, Spain
Robert J. Charnigo

⁶Pfizer Inc, Collegeville, Pennsylvania, USA
James A. Baumann

⁶Pfizer Inc, Collegeville, Pennsylvania, USA
Lynne Smith

⁶Pfizer Inc, Collegeville, Pennsylvania, USA
Joan M. Korth-Bradley

⁶Pfizer Inc, Collegeville, Pennsylvania, USA
Pablo Rendo

⁶Pfizer Inc, Collegeville, Pennsylvania, USA

Abstract

Summary

This prospective, open-label, postauthorisation safety surveillance study assessed clinically significant inhibitor development in patients with severe haemophilia A transitioning from moroctocog alfa or other factor VIII (FVIII) replacement products to reformulated moroctocog alfa (AF-CC). Males aged12 years with severe haemophilia A (FVIII:C) < 1 IU/dl), > 150 exposure days (EDs) to recombinant or plasma-derived FVIII products, and no detectable inhibitor at screening were enrolled. Primary end point was the incidence of clinically significant FVIII inhibitor development. Secondary end points included annualised bleeding rate (ABR), less-than-expected therapeutic effect (LETE), and FVIII recovery. Patients were assigned to one of two cohorts based on whether they were transitioning to moroctocog alfa (AF-CC) from moroctocog alfa (cohort 1; n=146) or from another recombinant or plasma-derived FVIII product (cohort 2; n=62). Mean number of EDs on study was 94 (range, 1–139). Six positive FVIII inhibitor results, as determined by local laboratories, were reported in four patients; none were confirmed by a central laboratory, no inhibitor-related clinical manifestations were reported, and all anti-FVIII antibody assays were negative. Median ABRs were 23.4 and 3.4 in patients categorised at baseline as following on-demand and prophylactic regimens, respectively; 86.5 % of bleeding episodes resolved after one infusion. LETE incidence was 0.06 % and 0.19 % in the on-demand and prophylaxis settings, respectively. FVIII recovery remained constant throughout the study. No new safety concerns were identified. This study found no increased risk of clinically significant FVIII inhibitor development in patients transitioning from moroctocog alfa or other FVIII replacement products to moroctocog alfa (AF-CC).

Keywords

Haemophilia A - factor VIII - moroctocog alfa - blood coagulation factor inhibitors - surveillance - safety

Volltext

Referenzen

References
1 Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet 2003; 361: 1801-1809.
2 Srivastava A, Brewer AK, Mauser-Bunschoten EP. et al. Guidelines for the management of haemophilia. Haemophilia 2013; 19: e1-e47.
3 Berntorp E, Shapiro AD. Modern haemophilia care. Lancet 2012; 379: 1447-1456.
4 Mannucci PM, Gdovin S, Gringeri A. et al. Transmission of hepatitis A to patients with haemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group. Ann Intern Med 1994; 120: 1-7.
5 Azzi A, Ciappi S, Zakvrzewska K. et al. Human parvovirus B19 infection in haemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates. Am J Hematol 1992; 39: 228-230.
6 Sharp CP, Lail A, Donfield S. et al. Virologic and clinical features of primary infection with human parvovirus 4 in subjects with haemophilia: frequent transmission by virally inactivated clotting factor concentrates. Transfusion 2012; 52: 1482-1489.
7 Ludlam CA, Turner ML. Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products. Br J Haematol 2006; 132: 13-24.
8 Draft Guidance for Industry: amendment to “Guidance for Industry: Revised Preventive Measures to Reduce the Possible Risk of Transmission of CreutzfeldtJakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products”. Food and Drug Administration. Available at: www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/UCM307137.pdf . Accessed June 26, 2014.
9 Meeks SL, Josephson CD. Should haemophilia treaters switch to albumin-free recombinant factor VIII concentrates. Curr Opin Hematol 2006; 13: 457-461.
10 Ehrenforth S, Kreuz W, Scharrer I. et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-598.
11 Franchini M, Coppola A, Rocino A. et al. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe haemophilia a: a 2013 update. Semin Thromb Haemost 2013; 39: 752-766.
12 Xi M, Makris M, Marcucci M. et al. Inhibitor development in previously treated haemophilia A patients: a systematic review, meta-analysis, and meta-regression. J Thromb Haemost 2013; 11: 1655-1662.
13 Gouw SC, van der Bom JG, Auerswald G. et al. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe haemophilia A: the CANAL cohort study. Blood 2007; 109: 4693-4697.
14 Gouw SC, van der Bom JG, Ljung R. et al. Factor VIII products and inhibitor development in severe haemophilia A. N Engl J Med 2013; 368: 231-239.
15 Calvez T, Chambost H, Claeyssens-Donadel S. et al. Recombinant factor VIII products and inhibitor development in previously untreated boys with severe haemophilia A. Blood. 2014 Epub ahead of print.
16 Darby SC, Keeling DM, Spooner RJ. et al. The incidence of factor VIII and factor IX inhibitors in the haemophilia population of the UK and their effect on subsequent mortality, 1977–99. J Thromb Haemost 2004; 2: 1047-1054.
17 Soucie JM, Cianfrini C, Janco RL. et al. Joint range-of-motion limitations among young males with haemophilia: prevalence and risk factors. Blood 2004; 103: 2467-2473.
18 Gringeri A, Mantovani LG, Scalone L. et al. Cost of care and quality of life for patients with haemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358-2363.
19 Dekoven M, Wisniewski T, Petrilla A. et al. Health-related quality of life in haemophilia patients with inhibitors and their caregivers. Haemophilia 2013; 19: 287-293.
20 Di Minno MN, Di MG, Di CM. et al. Cost of care of haemophilia with inhibitors. Haemophilia 2010; 16: e190-e201.
21 Lindvall K, von MS, Elmstahl S. et al. Increased burden on caregivers of having a child with haemophilia complicated by inhibitors. Paediatr Blood Cancer 2014; 61: 706-711.
22 Kempton CL, White GC. How we treat a haemophilia A patient with a factor VIII inhibitor. Blood 2009; 113: 11-17.
23 Iorio A, Puccetti P, Makris M. Clotting factor concentrate switching and inhibitor development in haemophilia A. Blood 2012; 120: 720-727.
24 Matino D, Lillicrap D, Astermark J. et al. Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity. Haemophilia 2014; 20: 200-206.
25 Summary of Product Characteristics: ReFacto AF.. European Medicine Agency. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000232/WC500049008.pdf . Accessed February 14, 2014.
26 Kelley B, Jankowski M, Booth J. An improved manufacturing process for Xyntha/ReFacto, AF. Haemophilia 2010; 16: 717-725.
27 Recht M, Nemes L, Matysiak M. et al. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII. Haemophilia 2009; 15: 869-880.
28 Fineberg NS, Fineberg SE, Anderson JH. et al. Immunologic effects of insulin lispro [Lys (B28), Pro (B29) human insulin] in IDDM and NIDDM patients previously treated with insulin. Diabetes 1996; 45: 1750-1754.
29 Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients. Semin Hematol 2001; 38: 44-51.
30 Manno CS, Butler RB, Cohen AR. Low recovery in vivo of highly purified factor VIII in patients with haemophilia. J Paediatr 1992; 121: 814-818.
31 Bjorkman S, Blanchette VS, Fischer K. et al. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost 2010; 8: 730-736.
32 Barnes C, Lillicrap D, Pazmino-Canizares J. et al. Pharmacokinetics of recombinant factor VIII (Kogenate-FS) in children and causes of inter-patient pharmacokinetic variability. Haemophilia 2006; 12 (Suppl. 04) 40-49.
33 Raes A, Van AS, Craen M. et al. A reference frame for blood volume in children and adolescents. BMC Paediatr 2006; 6: 3.
34 Aledort LM. Is the incidence and prevalence of inhibitors greater with recombinant products? Yes. J Thromb Haemost 2004; 2: 861-862.
35 Lusher JM. Is the incidence and prevalence of inhibitors greater with recombinant products? No. J Thromb Haemost 2004; 2: 863-865.
36 Peerlinck K, Arnout J, Gilles JG. et al. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost 1993; 69: 115-118.
37 Rosendaal FR, Nieuwenhuis HK, van den Berg HM. et al. A sudden increase in factor VIII inhibitor development in multitransfused haemophilia A patients in The Netherlands. Dutch Haemophilia Study Group. Blood 1993; 81: 2180-2186.
38 Aledort LM, Navickis RJ, Wilkes MM. Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies. J Thromb Haemost 2011; 9: 2180-2192.
39 Giles AR, Rivard GE, Teitel J. et al. Surveillance for factor VIII inhibitor development in the Canadian Haemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. Transfus Sci 1998; 19: 139-148.
40 Rubinger M, Lillicrap D, Rivard GE. et al. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose. Haemophilia 2008; 14: 281-286.
41 Bacon CL, Singleton E, Brady B. et al. Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE(R)). Haemophilia 2011; 17: 407-411.
42 Hay CR, Palmer BP, Chalmers EA. et al. The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparison. Haemophilia. 2014 Epub ahead of print.
43 Committee for Medicinal Products for Human Use.. Guideline on the Clinical Investigation of Recombinant and Human Plasma-Derived Factor VIII Products. London, United Kingdom:: European Medicines Agency;; 2011
44 Aledort LM. Harmonisation of clinical trial guidelines for assessing the risk of inhibitor development in haemophilia A treatment. J Thromb Haemost 2011; 9: 423-427.
45 Kempton CL, Soucie JM, Abshire TC. Incidence of inhibitors in a cohort of 838 males with haemophilia A previously treated with factor VIII concentrates. J Thromb Haemost 2006; 4: 2576-2581.
46 Glasser SP, Salas M, Delzell E. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems. J Clin Pharmacol 2007; 47: 1074-1086.
47 Meijer P, Verbruggen H, Arnout J. et al. Global ECAT survey on factor VIII inhibitor testing: results of an inter-laboratory pilot study. In: 36th Haemophilia Symposium Hamburg 2005. Heidelberg, Germany:: Springer Medizin Verlag;; 2007. pp. 75-77.

Zusatzmaterial

Zusatzmaterial (PDF)